Aligos Therapeutics, Inc.
corporate_fare Company Profile
Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALGS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ALGS spans 10-Q, 8-K, SCHEDULE 13D, DEFA14A.
Recent high-impact activity:
- Aligos 10-Q: $31.1M Cash Funds Operations Only Into Q1 2027, Going Concern Flagged
- Aligos Posts $2.09 Per-Share Q3 Loss as Cash Crunch Looms
- Aligos Doses First Patient in Phase 1 Trial of Next-Gen HBV Drug ALG-170675
- Aligos Q2 Loss Narrows to $1.5M on $28M Licensing Revenue, Cash Runway Through Q4
- Licensing revenue narrows Aligos' Q2 loss, but cash runway shrinks to Q4 2026 — going concern warning stands
Financial Snapshot
Short Interest & Short Volume
20.77 days to coverFINRA reported short interest of 677,218 shares in ALGS as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 20.8 days to cover at its recent average daily volume. On November 20, 2026, 62.0% of ALGS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.